CD30 targeting with brentuximab vedotin: A novel therapeutic approach to primary effusion lymphoma

Shruti Bhatt, Brittany M. Ashlock, Yasodha Natkunam, Victoria Sujoy, Jennifer Rose Chapman, Juan Carlos Ramos, Enrique A. Mesri, Izidore S. Lossos

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma characterized by short survival with current therapies, emphasizing the urgent need to develop new therapeutic approaches. Brentuximab vedotin (SGN-35) is an anti-CD30 monoclonal antibody (cAC10) conjugated by a protease-cleavable linker to a microtubule-disrupting agent, monomethyl auristatin E. Brentuximab vedotin is an effective treatment of relapsed CD30-expressing Classical Hodgkin and systemic anaplastic large cell lymphomas. Herein, we demonstrated that PEL cell lines and primary tumors express CD30 and thus may serve as potential targets for brentuximab vedotin therapy. In vitro treatment with brentuximab vedotin decreased cell proliferation, induced cell cycle arrest, and triggered apoptosis of PEL cell lines. Furthermore, in vivo brentuximab vedotin promoted tumor regression and prolonged survival of mice bearing previously reported UM-PEL-1 tumors as well as UM-PEL-3 tumors derived from a newly established and characterized Kaposi's sarcoma-associated herpesvirus- and Epstein-Barr virus-positive PEL cell line. Overall, our results demonstrate for the first time that brentuximab vedotin may serve as an effective therapy for PEL and provide strong preclinical indications for evaluation of brentuximab vedotin in clinical studies of PEL patients.

Original languageEnglish (US)
Pages (from-to)1233-1242
Number of pages10
JournalBlood
Volume122
Issue number7
DOIs
StatePublished - Aug 15 2013

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'CD30 targeting with brentuximab vedotin: A novel therapeutic approach to primary effusion lymphoma'. Together they form a unique fingerprint.

  • Cite this